Jämför metoder
Granska de valda metoderna sida vid sida; rader som skiljer sig är markerade.
| Bayesiansk Fas III Klinisk Prövning× | Adaptiv Fas III-klinisk prövning× | |
|---|---|---|
| Ämnesområde | Epidemiologi | Epidemiologi |
| Familj | Process / pipeline | Process / pipeline |
| Ursprungsår≠ | 1990s–2000s (widespread application) | 1969–2019 (sequential testing roots ~1969; formal adaptive design guidance 2010–2019) |
| Upphovsperson≠ | Donald A. Berry; David J. Spiegelhalter (formalization in clinical context) | Methodological foundations by Armitage et al. (1969); modern adaptive framework codified by FDA and ICH guidance (2010s) |
| Typ≠ | Confirmatory randomized controlled trial with Bayesian inference | Interventional confirmatory clinical trial with pre-specified interim adaptations |
| Ursprungskälla≠ | Spiegelhalter, D. J., Abrams, K. R., & Myles, J. P. (2004). Bayesian Approaches to Clinical Trials and Health-Care Evaluation. Wiley. ISBN: 978-0471499756 | International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). (2019). ICH E9(R1) Addendum on Estimands and Sensitivity Analysis in Clinical Trials to the Guideline on Statistical Principles for Clinical Trials. ICH Harmonised Guideline. link ↗ |
| Alias | Bayesian confirmatory trial, Bayesian RCT Phase III, Bayesian pivotal trial, BayesCT | adaptive confirmatory trial, seamless Phase II/III adaptive trial, adaptive pivotal trial, adaptive design Phase III |
| Närliggande≠ | 5 | 6 |
| Sammanfattning≠ | A Bayesian Phase III clinical trial is a large-scale, confirmatory randomized controlled trial that uses Bayesian statistical inference rather than conventional frequentist hypothesis testing to evaluate whether an experimental treatment meets pre-defined efficacy and safety thresholds. By combining prior evidence with accumulating trial data, it quantifies the probability that the treatment effect exceeds a clinically meaningful threshold, enabling more transparent decision-making under uncertainty. | An adaptive Phase III clinical trial is a confirmatory randomized controlled trial that incorporates pre-specified rules allowing modifications to the trial design — such as sample size re-estimation, dose selection, or population enrichment — based on accumulating interim data, while preserving the Type I error rate. It sits at the top of the evidence hierarchy and is used to obtain regulatory approval of new interventions. |
| ScholarGateDatamängd ↗ |
|
|